Heal Faster
Why should Rescuderm always be by your side?
The Rescuderm formula is an innovation made by scientists that change how we view and treat skin trauma and burns.
It does so by targeting the TRPV1 receptor. These receptors are present all across our skin and play a very important role.
The TRPV1 receptor has become well-known for its critical role in pain perception (feeling pain), detecting heat and acidity, as well as inflammation, and wound healing. [i] [ii] [iii] [iv]
The TRPV1 receptor also plays a key role in local release of neuropeptides that create inflammation we experience in burns and many other skin injuries.[v]
How is Rescuderm an all-in-one solution?
For a long time scientists have tried to mediate pain sensation and provide relief through the TRPV1 receptor.[vi]
Protons are one of a few specific molecules or ingredients that can bind to the TRPV1 receptor. In fact our own body at times releases protons to activate the TRPV1 receptor, serving as a natural agonist and answer to pain .[vii] [viii][ix]
Rescuderm uses this understanding as a foundation for its formula. The formulation is designed to bind to the TRPV1 receptor, competing with our body’s natural pain signals following trauma or burns to the skin.[x]
How the Rescuderm does so is through its unique “proton flux” within the formula, designed to provide a flow of protons to the affected area and local TRPV1 receptors.[xi]
What to expect when using Rescuderm
When you put Rescuderm onto a fresh wound, it immediately finds and binds to the activated TRPV1 receptors that are causing you to feel pain and inflammation, interrupting your body’s natural signals.
You’ll immediately notice an acute tingling sensation caused by TRPV1 receptor binding. Continued activation creates a desensitization and voila - pain stabilizes and subsides.
Along with less pain you’ll notice that things like reddening, bumpiness, and burning fade away. This is well documented this over a couple of clinical trials and studies with colleagues at the University of Toronto, University of Guelph, and Defense Research and Development Canada.
The Rescuderm formula was also designed to dry on over time, meaning that not only is Rescuderm working to reduce germ proliferation, but nothing new can get in, acting like a protective barrier or second skin.
Essentially, the Rescuderm formula serves as an all-in-one skin treatment for TRPV1-focussed injury and trauma.
All natural, non-toxic, fragrance free
On of top aiding your body's healing response and ward off infection, Rescuderm is non-prescription, Health Canada Approved (NHP-DIN#80026886), food-grade, ingestible, and organic.
Rescuderm, being made of organic active ingredients, is both safe to ingest and kid-friendly.
We want our product and story to be an open book, so feel free to click below to read more or contact us directly.
[i] Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997 Oct 23;389(6653):816-24. doi: 10.1038/39807. PMID: 9349813.
[ii] Gouin O, L'Herondelle K, Lebonvallet N, Le Gall-Ianotto C, Sakka M, Buhé V, Plée-Gautier E, Carré JL, Lefeuvre L, Misery L, Le Garrec R. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization. Protein Cell. 2017 Sep;8(9):644-661. doi: 10.1007/s13238-017-0395-5. Epub 2017 Mar 31. PMID: 28364279; PMCID: PMC5563280.
[iii] Bagood MD, Isseroff RR. TRPV1: Role in Skin and Skin Diseases and Potential Target for Improving Wound Healing. Int J Mol Sci. 2021 Jun 7;22(11):6135. doi: 10.3390/ijms22116135. PMID: 34200205; PMCID: PMC8201146.
[iv] Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998 Sep;21(3):531-43. doi: 10.1016/s0896-6273(00)80564-4. PMID: 9768840.
[v] Jhaveri MD, Elmes SJ, Kendall DA, Chapman V. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats. Eur J Neurosci. 2005 Jul;22(2):361-70. doi: 10.1111/j.1460-9568.2005.04227.x. PMID: 16045489.
[vi] Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med. 2009 Jan;15(1):14-22. doi: 10.1016/j.molmed.2008.11.004. Epub 2008 Dec 25. PMID: 19097938.
[vii] Lee BH, Zheng J. Proton block of proton-activated TRPV1 current. J Gen Physiol. 2015 Aug;146(2):147-59. doi: 10.1085/jgp.201511386. Epub 2015 Jul 13. PMID: 26170176; PMCID: PMC4516785.
[viii] Lee BH, Zheng J. Proton block of proton-activated TRPV1 current. J Gen Physiol. 2015 Aug;146(2):147-59. doi: 10.1085/jgp.201511386. Epub 2015 Jul 13. PMID: 26170176; PMCID: PMC4516785.
[ix] Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001 Sep 13;413(6852):203-10. doi: 10.1038/35093019. PMID: 11557989.
[x] Martineau L, Dosch HM. Management of bioburden with a burn gel that targets nociceptors. J Wound Care. 2007 Apr;16(4):157-64. doi: 10.12968/jowc.2007.16.4.27028. PMID: 17444381.
[xi] Hazan A, Kumar R, Matzner H, Priel A. The pain receptor TRPV1 displays agonist-dependent activation stoichiometry. Sci Rep. 2015 Jul 21;5:12278. doi: 10.1038/srep12278. PMID: 26194846; PMCID: PMC4508619.